Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Large Blend · Morgan Stanley

Discovery Portfolio Class L (MSKLX)

Ticker MSKLX · · Holdings as of Jun 30, 2026

Expense ratio
1.56%$156/yr per $10k
5-yr return
−5.9%annualized
1-yr return
+13.1%as of Dec 2025
Net assets
$801.5Mall share classes
Holdings
47

Bottom line

Is MSKLX a good fund? The bottom line

MSKLX is the Class L share class of Discovery Portfolio, an actively managed large blend mutual fund from Morgan Stanley.

Annual fees run 1.56% — about $156 a year on every $10,000 invested, more expensive than 85% of large blend funds we track.

It returned +13.1% over one year, −5.9% a year over five years, +12.5% a year over ten (as of Dec 31, 2025, per its prospectus).

With $801 million in net assets and 47 holdings, its largest position is Cloudflare Inc (13.9%) and the top 10 make up 66.2% of the portfolio.

What stands out

  • No front-end sales load

What to watch

  • Expensive for its category (1.56%)
  • 5-year return in the bottom quarter of its category
  • Concentrated: top 10 holdings are 66.2% of assets
  • 12b-1 marketing fee of 0.75% a year

Updated Nov 19, 2026

What MSKLX invests in

The Discovery Portfolio (the Fund) seeks long-term capital growth.

Under normal circumstances, the Adviser seeks to achieve the Funds investment objective by investing primarily in established and emerging companies, with capitalizations within the range of companies included in the Russell Midcap Growth Index, which as of December 31, 2025, ranged between $1.6 billion and $101.9 billion. The Adviser emphasizes a bottom-up stock selection process, seeking attractive investments on an individual company basis. The Adviser typically invests in unique companies it believes have sustainable competitive advantages with above average business visibility, the ability to deploy capital at high rates of return, strong balance sheets and an attractive risk/reward. The Adviser typically focuses a significant portion of the Funds investments in a limited number of issuers, which may be in the same industry, sector or geographic region. The Adviser actively…

From the fund's prospectus (filed Jan 28, 2026).

MSKLX performance

Average annual total returns
1 yr5 yr10 yr
MSKLX+13.1%−5.9%+12.5%
Large Blend median+13.8%+9.7%+10.9%

Source: Fund prospectus, as of Dec 31, 2025

Full MSKLX performance history →

What MSKLX costs

On a $10,000 investment, MSKLX's 1.56% expense ratio costs about $156 a year. The prospectus estimates $1,856 in total costs over 10 years (assuming 5% annual returns). The median large blend fund charges 0.83%.

See the full MSKLX fee table →

MSKLX top 10 holdings

#Holding% of fund
1Cloudflare Inc13.90%
2Royalty Pharma PLC9.29%
3Affirm Holdings Inc7.46%
4Aurora Innovation Inc7.11%
5IonQ Inc6.03%
6Roivant Sciences Ltd5.48%
7Databricks, Inc. Series H Preferred Shares4.66%
8QXO Inc4.46%
9ROBLOX Corp4.14%
10Opendoor Technologies Inc3.63%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 66.2% of the fund. See all top 25 holdings and asset mix →

Alternatives to MSKLX

More funds like MSKLX →

MSKLX FAQ

What is the expense ratio of MSKLX?
MSKLX's expense ratio is 1.56%, which works out to about $156 a year for every $10,000 invested. The prospectus estimates total costs of $1,856 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is MSKLX a good investment?
It depends on your goals, but the data points to: no front-end sales load; expensive for its category (1.56%); 5-year return in the bottom quarter of its category; concentrated: top 10 holdings are 66.2% of assets; 12b-1 marketing fee of 0.75% a year. This is general information, not personalized advice.
What does MSKLX hold?
MSKLX's largest holdings are Cloudflare Inc (13.9%), Royalty Pharma PLC (9.3%), Affirm Holdings Inc (7.5%), Aurora Innovation Inc (7.1%), IonQ Inc (6.0%). It holds 47 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is MSKLX's 5-year return?
MSKLX returned −5.9% a year over the five years ending Dec 31, 2025, and +12.5% a year over ten years. Past performance does not guarantee future results.
Does MSKLX have a sales load?
No. MSKLX has no front-end sales charge.
Who manages MSKLX?
MSKLX is offered by Morgan Stanley through Morgan Stanley Institutional Fund Trust.